Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Front Immunol. 2024 Sep 25;15:1425349. doi: 10.3389/fimmu.2024.1425349. eCollection 2024.
Dynamic cellular and molecular adaptations in early life significantly impact health and disease. Upon birth, newborns are immediately challenged by their environment, placing urgent demands on the infant immune system. Adenosine deaminases (ADAs) are enzymatic immune modulators present in two isoforms - ADA-1 and ADA-2. Infants exhibit low ADA activity, resulting in high plasma adenosine concentrations and a consequent anti-inflammatory/anti-Th1 bias. While longitudinal studies of plasma ADA have been conducted in infants in The Gambia (GAM), little is known regarding ADA trajectories in other parts of the world.
Herein, we characterized plasma ADA activity in an infant cohort in Papua New Guinea (PNG; n=83) and compared to ontogeny of ADA activity in a larger cohort in GAM (n=646). Heparinized peripheral blood samples were collected at day of life (DOL) 0, DOL7, DOL30, and DOL128. Plasma ADA-1, ADA-2, and total ADA activities were measured by chromogenic assay.
Compared to GAM infants, PNG infants had significantly lower ADA-1 (0.9-fold), ADA-2 (0.42-fold), and total ADA (0.84-fold) activities at birth which converged by DOL30.
Overall, discovery of a distinct baseline and a consistent pattern of increasing plasma ADA activity in early life in two genetically and geographically distinct populations validates and extends previous findings on the robustness of early life immune ontogeny.
生命早期细胞和分子的动态适应对健康和疾病有重大影响。新生儿一出生就立即面临环境的挑战,这对婴儿的免疫系统提出了紧迫的要求。腺苷脱氨酶(ADA)有两种同工酶形式——ADA-1 和 ADA-2,是存在于体内的酶免疫调节剂。婴儿的 ADA 活性较低,导致血浆中腺苷浓度升高,继而产生抗炎/抗 Th1 偏向。虽然在冈比亚(GAM)的婴儿中进行了关于血浆 ADA 的纵向研究,但对于世界其他地区 ADA 轨迹的了解甚少。
本研究在巴布亚新几内亚(PNG;n=83)的婴儿队列中描述了血浆 ADA 活性,并与 GAM 中更大队列的 ADA 活性发育进行了比较(n=646)。在出生后第 0、7、30 和 128 天采集肝素化外周血样本。通过比色法测定血浆 ADA-1、ADA-2 和总 ADA 活性。
与 GAM 婴儿相比,PNG 婴儿出生时的 ADA-1(低 0.9 倍)、ADA-2(低 0.42 倍)和总 ADA(低 0.84 倍)活性明显较低,到第 30 天基本达到一致。
总之,在两个遗传和地理上截然不同的人群中发现了明显不同的基线和早期生命中血浆 ADA 活性增加的一致模式,这验证并扩展了早期生命免疫发生的稳健性的先前发现。